Skip to main content

Aurinia Pharmaceuticals Inc.

AUPH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001600620

In the last 90 days, Aurinia Pharmaceuticals Inc. insiders filed 0 open-market purchases and 3 sales; 285 institutions reported holding it in 13F filings for Q2 2026, worth $1.34B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 17, 2026
$2.06B
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $735.9K in total
3
13F holdersQ2 2026, +24 vs. previous quarter
285
13F valueReported value at the end of Q2 2026
$1.34B
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$283.1M
+20.4% year over year
Net income, FY2025
$287.2M
+4,893.1% year over year
Free cash flow, FY2025
–
No comparable prior period
Revenue, Q3 FY2026
$83.7M
+13.9% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
7.14M
Shares sold short
Change
−642.7K
−8.3% vs. previous
Days to cover
10.31
At average daily volume

Superinvestors holding AUPH, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding AUPH at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Aurinia Pharmaceuticals Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 16, 2026 (view filing)4:25 PM ETNov 133 daysRobertson Stephen P.Chief Legal OfficerSSale−11.9K$15.97−$189.5K−2.0%577.0K after
Sep 11, 2026 (view filing)4:26 PM ETSep 101 dayRobertson Stephen P.Chief Legal OfficerSSale−11.9K$15.95−$190.4K−2.0%588.8K after
Aug 25, 2026 (view filing)9:29 PM ETAug 214 daysRobertson Stephen P.Chief Legal OfficerSSale−21.0K$16.97−$355.9K−3.4%600.8K after
Jun 2, 2026 (view filing)9:54 PM ETMay 29-Jun 24 daysTang Kevin C and 1 otherChief Executive OfficerPPurchase+814.6K$15.29+$12.5M+6.7%13.0M after5 lots
Mar 3, 2026 (view filing)Feb 27-Mar 34 daysTang Kevin CDirectorPPurchase+900.0K$14.10+$12.7M+7.9%12.2M after6 lots
Aug 5, 2025 (view filing)Aug 14 daysKeenan GregChief Medical OfficerSSale−20.0K$10.50−$210.0K−13.0%133.5K after
Aug 5, 2025 (view filing)Aug 1-54 daysTang Kevin CDirectorPPurchase+1.30M$10.45+$13.6M+13.0%11.3M after3 lots
Mar 7, 2025 (view filing)Mar 7Same dayKeenan GregChief Medical OfficerSSale−8.30K$8.23−$68.4K−5.1%153.5K after
Mar 4, 2025 (view filing)Mar 3-41 dayGreenleaf PeterChief Executive OfficerSSale−360.5K$7.96−$2.87M−16.8%1.79M after2 lots
Mar 4, 2025 (view filing)Mar 31 dayKeenan GregChief Medical OfficerSSale−12.2K$8.00−$97.9K−7.0%161.8K after

Top 10 13F holders, Q2 2026

See all 285 holders

The largest institutional positions in Aurinia Pharmaceuticals Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding AUPH in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Tang Capital Management LLC13,044,106$221.4M10.05%+814,606+6.7%Added
BlackRock, Inc.8,193,085$139.0M0.00%+347,564+4.4%Added
Goldman Sachs Group Inc5,619,401$95.4M0.01%+4,185,893+292.0%Added
NEA Management Company, LLC3,969,834$67.4M4.24%00.0%Unchanged
Two Sigma Investments, LP3,467,514$58.8M0.04%+38,809+1.1%Added
Arrowstreet Capital, Limited Partnership3,264,062$55.4M0.02%−20,306−0.6%Reduced
State Street Corp2,589,615$43.9M0.00%+62,516+2.5%Added
Morgan Stanley2,308,244$39.2M0.00%+75,696+3.4%Added
Marshall Wace, LLP2,044,007$34.7M0.03%+169,410+9.0%Added
Geode Capital Management, LLC1,701,152$28.9M0.00%+165,143+10.8%Added

Holders of 5% or more of AUPH

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Aurinia Pharmaceuticals Inc..

Largest holders of AUPH from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Tang Capital Management LLC13D/A10.00%13.0M shares+0.80 ppfrom 9.20%Sep 12, 20245 filingsJun 4, 2026SEC